黑料吃瓜群网

Australians with paroxysmal nocturnal haemoglobinuria (PNH) 鈥� a condition that produces defective blood cells 鈥� will have access to a new treatment through the Pharmaceutical Benefits Scheme (PBS).

PNH is a rare, potentially life-threatening condition in which red blood cells break apart prematurely. Symptoms occur because of the production of defective blood cells and because the bone marrow does not produce enough blood cells.

The specific symptoms and progression of the disorder vary greatly and some individuals may have mild symptoms which remain stable for many years, while others may have serious symptoms which can progress to cause life-threatening complications. Blood clots are a very serious complication of PNH.

From 1 March, Ultomiris (ravulizumab) will be listed for the first time for patients with PNH. Ultomiris protects the red blood cells from damage and destruction by blocking the body鈥檚 inflammatory response.

Minister for Health and Aged Care Greg Hunt said around 160 Australians each year will benefit from the listing of Ultomiris on the PBS.

鈥淲ithout subsidy, Australians would pay around $550,000 per year for treatment, instead from March 1, they鈥檒l pay $42.50 per script, or just $6.80 with a concession card,鈥� Minister Hunt said.

At the same time, Soliris (eculizumab), which has been available through the Life Savings Drug Program for the treatment of PNH, will move to the PBS.

This PBS listing has been recommended by the independent Pharmaceutical Benefits Advisory Committee.

Image credit:聽漏stock.adobe.com/au/dTosh